EP3893919A4 - PEGYLATED GROWTH HORMONE ANTAGONISTS - Google Patents
PEGYLATED GROWTH HORMONE ANTAGONISTS Download PDFInfo
- Publication number
- EP3893919A4 EP3893919A4 EP19896879.4A EP19896879A EP3893919A4 EP 3893919 A4 EP3893919 A4 EP 3893919A4 EP 19896879 A EP19896879 A EP 19896879A EP 3893919 A4 EP3893919 A4 EP 3893919A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- growth hormone
- hormone antagonists
- pegylated growth
- pegylated
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122853 Growth hormone antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/216,230 US10874717B2 (en) | 2015-07-07 | 2018-12-11 | Pegylated growth hormone antagonists |
| PCT/US2019/065385 WO2020123450A1 (en) | 2018-12-11 | 2019-12-10 | Pegylated growth hormone antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3893919A1 EP3893919A1 (en) | 2021-10-20 |
| EP3893919A4 true EP3893919A4 (en) | 2022-11-30 |
Family
ID=71076634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19896879.4A Pending EP3893919A4 (en) | 2018-12-11 | 2019-12-10 | PEGYLATED GROWTH HORMONE ANTAGONISTS |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3893919A4 (en) |
| JP (2) | JP2022511951A (en) |
| CA (1) | CA3121241A1 (en) |
| WO (1) | WO2020123450A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250101076A1 (en) * | 2023-09-22 | 2025-03-27 | Molecular Technologies Laboratories Llc | Growth hormone receptor antagonists exhibiting increased receptor binding properties and increased serum half-life |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170007711A1 (en) * | 2015-07-07 | 2017-01-12 | Richard S. Brody | Pegylated growth hormone antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG135176A1 (en) | 2004-02-02 | 2007-09-28 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
| CN103690936A (en) * | 2004-12-22 | 2014-04-02 | Ambrx公司 | Modified human growth hormone |
| US10874717B2 (en) | 2015-07-07 | 2020-12-29 | Burr Oak Therapeutics LLC | Pegylated growth hormone antagonists |
| WO2019211842A1 (en) | 2018-04-30 | 2019-11-07 | Opko Biologics Ltd. | Long-acting human growth hormone-antagonists and methods of producing the same |
-
2019
- 2019-12-10 EP EP19896879.4A patent/EP3893919A4/en active Pending
- 2019-12-10 CA CA3121241A patent/CA3121241A1/en active Pending
- 2019-12-10 WO PCT/US2019/065385 patent/WO2020123450A1/en not_active Ceased
- 2019-12-10 JP JP2021533244A patent/JP2022511951A/en active Pending
-
2024
- 2024-11-08 JP JP2024195736A patent/JP2025026898A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170007711A1 (en) * | 2015-07-07 | 2017-01-12 | Richard S. Brody | Pegylated growth hormone antagonists |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE Geneseq [online] 9 March 2017 (2017-03-09), "Human mutant growth hormone (GH) protein (G120K/H151C), SEQ ID 18.", XP055943327, retrieved from EBI accession no. GSP:BDN14369 Database accession no. BDN14369 * |
| DATABASE Geneseq [online] 9 March 2017 (2017-03-09), "Human mutant growth hormone (GH) protein (G120K/N99C), SEQ ID 14.", XP055944163, retrieved from EBI accession no. GSP:BDN14365 Database accession no. BDN14365 * |
| See also references of WO2020123450A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025026898A (en) | 2025-02-26 |
| JP2022511951A (en) | 2022-02-01 |
| EP3893919A1 (en) | 2021-10-20 |
| CA3121241A1 (en) | 2020-06-18 |
| WO2020123450A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3814381A4 (en) | TRISPECIFIC ANTAGONISTS | |
| SG11202104136YA (en) | Heterodimeric fc-fused proteins | |
| JP1654103S (en) | cup | |
| JP1663302S (en) | cup | |
| LT3762380T (en) | PHENYLPYROLIDINONE FORMILPEPTIDO 2 RECEPTOR ANTAGONISTS | |
| HUE053862T2 (en) | Articulated self-propelled | |
| IL283445A (en) | Spray preparation | |
| EP3753396C0 (en) | TRIMMER | |
| EP3750579A4 (en) | INJECTOR | |
| EP4219831C0 (en) | CONNECTING STONE ARRANGEMENT | |
| EP3886654C0 (en) | CUP | |
| EP4069702A4 (en) | SSTR5 ANTAGONISTS | |
| EP3826702A4 (en) | INJECTOR | |
| MA53493A (en) | POLYPEPTIDES LURES | |
| PL3613739T3 (en) | INTEGRIN ANTAGONISTS | |
| EP3802565A4 (en) | POLYPEPTIDES | |
| EP3773087A4 (en) | CUP | |
| GB201815629D0 (en) | Antagonists | |
| EP3851448A4 (en) | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | |
| EP3858868A4 (en) | POLYPEPTIDE COMPOSITION | |
| TWI800634B (en) | ceramic structure | |
| EP3777509A4 (en) | MOWER | |
| EP3893919A4 (en) | PEGYLATED GROWTH HORMONE ANTAGONISTS | |
| EP3904039C0 (en) | INJECTOR | |
| DK3852523T3 (en) | Bait station |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210705 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/61 20060101ALI20220725BHEP Ipc: A61K 47/60 20170101ALI20220725BHEP Ipc: A61K 38/27 20060101AFI20220725BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20221031 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/61 20060101ALI20221025BHEP Ipc: A61K 47/60 20170101ALI20221025BHEP Ipc: A61K 38/27 20060101AFI20221025BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240301 |